Positive IdeS phase I data published in scientific journal PLOS ONE
Hansa Medical AB (publ) today announced that the results from the phase I trial of its candidate drug have been published in PLOS ONE .The trial was a first-in-man, double blind, randomized study with single-ascending doses of IdeS in twenty-nine healthy male subjects who were given intravenous doses of placebo or IdeS at 0.01, 0.04, 0.12 and 0.24 mg/kg body weight. IdeS was considered safe with no serious adverse events. Furthermore, IdeS converted plasma IgG into single cleaved IgG (scIgG) with impressive efficacy within minutes after